Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2023-12-28 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
2023年第六次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 sixth extraordinary general meeting of shareholders of Sichuan Zitonggong Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, agenda items, voting results, and changes in board and supervisory personnel. The content focuses on shareholder meeting decisions, including board member elections and approval of various proposals. There is no presentation material, financial statements, or earnings data. The document is not a report itself but a formal announcement of voting results and decisions made at a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail confirm it is not a brief report publication announcement or a simple regulatory filing. Confidence is high due to the explicit voting results and meeting details provided.
2023-12-28 Chinese
2023年第二次职工代表大会公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the company's 2023 second employee representative meeting. It details the meeting's convening, attendance, and the election of a supervisory board member. There is no financial data, no mention of annual or interim reports, no audit information, no voting results from a shareholder meeting, and no regulatory certifications. The document is a corporate governance announcement related to internal company meetings and board composition but not a change in senior management or board members per se. It is not a report or presentation but an official announcement of a meeting resolution. Given the content and nature, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other specific categories.
2023-12-28 Chinese
关于使用自有闲置资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes specifics about the amounts, types of financial products, expected yields, investment directions, and risk control measures. The document is a disclosure of ongoing financing activities related to the company's capital management, specifically the use of idle funds for short-term financial investments. It does not contain financial statements, audit opinions, or management discussions of financial results. It is not an annual or interim report, nor is it a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it provides updates on the company's financing activities and capital usage.
2023-12-28 Chinese
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2023年第六次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, qualifications of attendees, and voting results of the company's 2023 sixth extraordinary general meeting (临时股东大会). It details the legality and compliance of the meeting process and the validity of the resolutions passed. The document does not contain financial statements or financial performance data, nor is it a report of voting results alone. It is a legal opinion related to a shareholders' meeting, focusing on procedural and legal compliance rather than the meeting materials or voting results announcement. Therefore, it does not fit categories like Annual Report, Earnings Release, or Declaration of Voting Results. It is best classified as a Regulatory Filing (RNS) because it is a legal compliance document related to corporate governance and shareholder meeting procedures, which does not fit other more specific categories.
2023-12-28 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It includes specifics about the amounts, types of financial products, expected yields, investment directions, and risk disclosures. The document references board meetings approving the use of idle raised funds for purchasing financial products and provides detailed tables of entrusted financial products, both current and matured. The content focuses on capital management and financing activities related to the company's raised funds, rather than financial results, audit opinions, or management changes. It is not a full financial report, earnings release, or regulatory certification. The document is a capital/financing update about the use of idle raised funds in financial products, consistent with the Capital/Financing Update (CAP) category.
2023-12-14 Chinese
关于使用自有闲置资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the company's use of idle funds to purchase financial products, including specifics on amounts, types of products, expected returns, and risk management. It includes disclosures required by the Beijing Stock Exchange rules about the scale of these investments relative to net assets. The document is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is a regulatory announcement about capital usage and investment activities, specifically about financing and capital management. Therefore, it fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about financing activities, not just a brief notice or report publication announcement.
2023-12-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.